Trial site
Klinische Forschung Hannover-Mitte GmbH
Hanover, 30159, GermanyNot linked to an institution yet
- 12running trials
- 16closed trials
The trials here
What the 28 trials at this site are about, from their registry records.
- Phase
- Phase 320 trials
- Phase 24 trials
- Phase 12 trials
- Phase 42 trials
- Status
- Completed15 trials
- Recruiting8 trials
- Active, not recruiting3 trials
- Not yet recruiting1 trial
- Terminated1 trial
- Lead sponsor
- AbbVie2 trials
- Ascletis Pharma (China) Co. Ltd.2 trials
- AstraZeneca2 trials
- Dr. Willmar Schwabe GmbH & Co. KG2 trials
- ModernaTX, Inc.2 trials
- and 17 more
Running trials
Recruiting
A Study to evaluate effect of AZD6234 in adult participants with Type 2 Diabetes Mellitus and obesity or overweight
2025-524616-11-00· Phase 3· AstraZeneca AB· Source
Not yet recruiting
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of CD388, a Novel Long-Acting Antiviral Conjugate, for the Prevention of Influenza in Adults and Adolescents at Higher Risk of Developing Influenza Complications
2026-527531-33-00· Phase 3· Cidara Therapeutics Inc.· Source
Recruiting
Efficacy and Safety of Once-Daily Oral ASC30 Compared with Placebo in Participants with Obesity or Overweight with Weight-Related Comorbidities
2026-526172-23-00· Phase 3· Ascletis Pharma (China) Co. Ltd.· Source
Recruiting
Efficacy and Safety of Once-Daily Oral ASC30 Compared with Placebo in Participants with Obesity or Overweight with Type 2 Diabetes Mellitus
2026-526336-39-00· Phase 3· Ascletis Pharma (China) Co. Ltd.· Source
Recruiting
A study on the efficacy of a vaccine against influenza in adults ≥65 years of age
2026-526682-14-00· Phase 3· GlaxoSmithKline Biologicals· Source
Recruiting
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
NCT07784725· Phase 3· AstraZeneca· Source
Active, not recruiting
Silexan® in mild to moderate major depressive disorder
2025-521744-37-00· Phase 3· Dr. Willmar Schwabe GmbH & Co. KG· Source
Active, not recruiting
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
NCT07153471· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370· Phase 3· Boehringer Ingelheim· Source
Active, not recruiting
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
NCT06154837· Phase 1· GlaxoSmithKline· Source
Recruiting
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
NCT05712200· Phase 3· Anthos Therapeutics, Inc.· Source
Recruiting
Randomized, double-blind, placebo-controlled, multi-centre trial to evaluate the efficacy, safety and tolerability of oral treatment with living bacteria of E. coli DSM 17252 (Symbioflor®2) in patients with diarrhoea-predominant irritable bowel syndrome (IBS-D)
2024-512104-19-00· Phase 4· SymbioPharm GmbH· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A trial to find the effect of Ginkgo biloba extract EGb 761® and how safe it is in participants with cognitive impairment associated with post COVID-19 syndrome
2024-517199-39-00· Phase 2· Dr. Willmar Schwabe GmbH & Co. KG· Source
Completed
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
NCT06602024· Phase 3· ModernaTX, Inc.· Source
Completed
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis
2023-504564-42-00· Phase 2· Anaptysbio Inc.· Source
Completed
A proof of concept and dose-finding study of XXB750 in patients with heart failure
2023-504678-39-00· Phase 2· Novartis Pharma AG· Source
Completed
A trial of prednisolone in combination with SPI-62 in participants with polymyalgia rheumatica (PMR)
2023-507721-41-00· Phase 1· Sparrow Pharmaceuticals Inc.· Source
Completed
The Celljuvant study, A phase 3 Immunogenicity and Safety Study of aQIVc HD Vaccine in Adults aged 50 years and older.
2023-503763-42-00· Phase 3· Seqirus UK Limited· Source
Completed
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older
NCT06015282· Phase 3· Seqirus· Source
Completed
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
NCT05748483· Phase 3· AbbVie· Source
Completed
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
NCT06040086· Phase 3· AstraZeneca· Source
Completed
Efficacy and Tolerability of Tasipimidine in Sleepless Patients
NCT06956495· Phase 2· Orion Corporation, Orion Pharma· Source
Active, not recruiting
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
NCT05968430· Phase 3· Mineralys Therapeutics Inc.· Source
Completed
A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older
NCT05566639· Phase 3· ModernaTX, Inc.· Source
Completed
Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol,is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.
2024-511263-28-00· Phase 4· Novartis Pharma AG· Source
Completed
A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia
NCT05079919· Phase 3· Ionis Pharmaceuticals, Inc.· Source
Completed
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
NCT04686136· Phase 3· AbbVie· Source
Terminated
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
NCT04241068· Phase 3· Biogen· Source
Report an error